189 related articles for article (PubMed ID: 23095875)
1. Specific immunotherapy in grass pollen allergy.
Mailhol C; Didier A
Hum Vaccin Immunother; 2012 Oct; 8(10):1544-7. PubMed ID: 23095875
[TBL] [Abstract][Full Text] [Related]
2. [Allergen-specific immunotherapy in the treatment of pollen allergy].
Mailhol C; Didier A
Rev Mal Respir; 2013 Feb; 30(2):142-51. PubMed ID: 23419445
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
4. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
5. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
[TBL] [Abstract][Full Text] [Related]
6. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
Didier A; Wahn U; Horak F; Cox LS
Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
8. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunotherapy for allergic rhinitis.
Wilson DR; Torres LI; Durham SR
Cochrane Database Syst Rev; 2003; (2):CD002893. PubMed ID: 12804442
[TBL] [Abstract][Full Text] [Related]
10. Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study.
Shah-Hosseini K; Krudewig EM; Hadler M; Karagiannis E; Mösges R
Adv Ther; 2017 Jun; 34(6):1382-1397. PubMed ID: 28455783
[TBL] [Abstract][Full Text] [Related]
11. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
[TBL] [Abstract][Full Text] [Related]
12. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
Köberlein J; Mösges R
Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
[TBL] [Abstract][Full Text] [Related]
13. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
15. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.
Valovirta E; Petersen TH; Piotrowska T; Laursen MK; Andersen JS; Sørensen HF; Klink R;
J Allergy Clin Immunol; 2018 Feb; 141(2):529-538.e13. PubMed ID: 28689794
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis.
Wilson DR; Lima MT; Durham SR
Allergy; 2005 Jan; 60(1):4-12. PubMed ID: 15575924
[TBL] [Abstract][Full Text] [Related]
18. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
19. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.
Rak S; Yang WH; Pedersen MR; Durham SR
Qual Life Res; 2007 Mar; 16(2):191-201. PubMed ID: 17033900
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
Malling HJ; Montagut A; Melac M; Patriarca G; Panzner P; Seberova E; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
